Kiniksa Pharmaceuticals International (KNSA) investor relations material

Executive summary

• Q1 2026 net revenue reached $214.3M, up 56% year-over-year, driven by ARCALYST adoption and strong commercial execution, with over 4,550 prescribers since launch.

• Net income rose to $22.6M from $8.5M in Q1 2025, reflecting revenue growth outpacing expense increases.

• Cash balance as of March 31, 2026, was $468.1M, with no debt and continued annual cash flow positivity.

• Raised full-year 2026 ARCALYST net revenue guidance to $930M–$945M, up from $900M–$920M, reflecting robust Q1 momentum.

• Advanced pipeline with KPL-387 Phase II data expected in H2 2026 and Phase III initiation by year-end; KPL-1161 Phase I planned by year-end 2026.

Financial highlights

• Q1 2026 ARCALYST net revenue was $214.3M, up from $137.8M in Q1 2025.

• Net income for Q1 2026 was $22.6M, up from $8.5M in Q1 2025.

• Total operating expenses rose to $185.0M from $124.5M year-over-year.

• Operating income for Q1 2026 was $29.3M, compared to $13.3M in Q1 2025.

• Cash, cash equivalents, and short-term investments stood at $468.1M as of March 31, 2026.

Outlook and guidance

• Full-year 2026 ARCALYST net product revenue guidance increased to $930M–$945M, reflecting strong Q1 performance.

• Operating plan expected to remain cash flow positive on an annual basis.

• KPL-387 Phase II data expected in H2 2026; Phase III trial to initiate by year-end.

• KPL-1161 Phase I study planned to start by year-end 2026.

• Cash and expected inflows projected to fund operations and capital expenditures for at least the next 12 months.